throbber

`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`
`
`CUBICIN safely and effectively. See full prescribing information
`
`
`
`
`for CUBICIN.
`
`CUBICIN® (daptomycin for injection), for Intravenous Use
`
`Initial U.S. Approval: 2003
`
`
`
`--------------------------- RECENT MAJOR CHANGES ---------------------------
`Warnings and Precautions, Development of Drug-Resistant
`10/2021
`Bacteria (5.12)
`
`
`----------------------------INDICATIONS AND USAGE----------------------------
`
`
`
`CUBICIN is a lipopeptide antibacterial indicated for the treatment of:
`
`Complicated skin and skin structure infections (cSSSI) in adult
`
`
`and pediatric patients (1 to 17 years of age) (1.1) and,
`Staphylococcus aureus bloodstream infections (bacteremia), in
`
`
`including
`infective
`adult patients
`those with
`right-sided
`endocarditis, (1.2)
`
`Staphylococcus aureus bloodstream infections (bacteremia) in
`
`
`pediatric patients (1 to 17 years of age). (1.3)
`
`Limitations of Use:
`
`CUBICIN is not indicated for the treatment of pneumonia. (1.4)
`
`
`
`
`CUBICIN is not indicated for the treatment of left-sided infective
`
`
`
`
`endocarditis due to S. aureus. (1.4)
`
`CUBICIN is not recommended in pediatric patients younger than
`
`
`one year of age due to the risk of potential effects on muscular,
`
`neuromuscular, and/or nervous systems (either peripheral and/or
`
`
`central) observed in neonatal dogs. (1.4)
`
`To reduce the development of drug-resistant bacteria and maintain the
`effectiveness of CUBICIN and other antibacterial drugs, CUBICIN
`
`
`
`
`should be used to treat or prevent infections that are proven or strongly
`
`
`
`suspected to be caused by bacteria. (1.5)
`
`----------------------- DOSAGE AND ADMINISTRATION -----------------------
`
`
`
`
`Adult Patients
`Administer to adult patients intravenously in 0.9% sodium
`
`
`
`
`chloride, either by injection over a 2-minute period or by infusion
`
`over a 30-minute period. (2.1, 2.7)
`
`
`Recommended dosage regimen for adult patients (2.2, 2.4, 2.6):
`
`Creatinine
`Dosage Regimen
`Clearance
`
`cSSSI
`
`
`S. aureus
`(CLCR)
`For 7 to 14 days
`Bacteremia
`For 2 to 6 weeks
`
`6 mg/kg once
`every 24 hours
`6 mg/kg once
`every 48 hours*
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`≥30 mL/min
`
`
`4 mg/kg once every
`24 hours
`
`4 mg/kg once every
`48 hours*
`
`
`<30 mL/min,
`including
`hemodialysis and
`CAPD
`*Administered following hemodialysis on hemodialysis days.
`Pediatric Patients
`
`
`
`
`Unlike in adults, do NOT administer by injection over a two
`
`
`(2) minute period to pediatric patients. (2.1, 2.7)
`Administer to pediatric patients intravenously in 0.9% sodium
`
`
`chloride, by infusion over a 30- or 60-minute period, based on
`
`age. (2.1, 2.7)
`
`
`
`
`
`Recommended dosage regimen for pediatric patients (1 to 17
`
`years of age) with cSSSI, based on age (2.3):
`
`Age group
`Dosage*
`
`
`
`
`
`
`
`
`
`Duration of
`therapy
`
`12 to 17 years
`
`
`7 to 11 years
`
`
`2 to 6 years
`
`
`5 mg/kg once every 24 hours
`
`
`infused over 30 minutes
`
`7 mg/kg once every 24 hours
`infused over 30 minutes
`9 mg/kg once every 24 hours
`infused over 60 minutes
`10 mg/kg once every 24 hours
`1 to less than
`infused over 60 minutes
`2 years
`* Recommended dosage is for pediatric patients (1 to 17 years of
`age) with normal renal function. Dosage adjustment for pediatric
`patients with renal impairment has not been established.
`Recommended dosage regimen for pediatric patients (1 to 17
`
`
`
`
`
`
`
`years of age) with S. aureus bacteremia, based on age (2.5):
`
`
`Up to 14 days
`
`
`
`
`Reference ID: 4878697
`
`Age group
`
`
`Dosage*
`
`Duration of
`therapy
`
`
`
`
`
`
`
`
`12 to 17 years
`
`
`7 to 11 years
`
`
`Up to 42 days
`
`
`
`7 mg/kg once every 24 hours
`
`
`infused over 30 minutes
`
`9 mg/kg once every 24 hours
`infused over 30 minutes
`12 mg/kg once every 24 hours
`1 to 6 years
`
`infused over 60 minutes
`*Recommended dosage is for pediatric patients (1 to 17 years of age)
`with normal renal function. Dosage adjustment for pediatric patients
`with renal impairment has not been established.
`There are two formulations of daptomycin that have differences
`
`
`
`follow
`the
`concerning storage and reconstitution. Carefully
`
`reconstitution and storage procedures in labeling. (2.7)
`
`Do not use in conjunction with ReadyMED® elastomeric infusion
`
`
`
`pumps in adult and pediatric patients. (2.9)
`
`
`--------------------- DOSAGE FORMS AND STRENGTHS ---------------------
`
`
`
`For Injection: 500 mg lyophilized powder for reconstitution in a single-
`dose vial (3)
`
`
`
`------------------------------- CONTRAINDICATIONS-------------------------------
`
` Known hypersensitivity to daptomycin (4)
`
`
`
`----------------------- WARNINGS AND PRECAUTIONS -----------------------
`
`
`
` Anaphylaxis/hypersensitivity reactions (including life-threatening):
`
`Discontinue CUBICIN and treat signs/symptoms. (5.1)
`
`
` Myopathy and rhabdomyolysis: Monitor CPK levels and follow
`
`muscle pain or weakness; if elevated CPK or myopathy occurs,
`
`consider discontinuation of CUBICIN. (5.2)
`
`
`
` Eosinophilic pneumonia: Discontinue CUBICIN and consider
`treatment with systemic steroids. (5.3)
`
` Drug Reaction with Eosinophilia and Systemic Symptoms
`
`institute appropriate
`(DRESS): Discontinue CUBICIN and
`treatment. (5.4)
`
`(TIN): Discontinue CUBICIN and
`Tubulointerstitial Nephritis
`institute appropriate treatment. (5.5)
`
`
`
`
` Peripheral neuropathy: Monitor for neuropathy and consider
`
`discontinuation. (5.6)
`
`
`
` Potential nervous system and/or muscular system effects in
`
`
`pediatric patients younger than 12 months: Avoid use of CUBICIN
`
`in this age group. (5.7)
`
`
` Clostridioides difficile–associated diarrhea: Evaluate patients if
`
`diarrhea occurs. (5.8)
`
`
`
` Persisting or relapsing S. aureus bacteremia/endocarditis: Perform
`
`
`susceptibility testing and rule out sequestered foci of infection.
`
`(5.9)
`
` Decreased efficacy was observed in adult patients with moderate
`baseline renal impairment. (5.10)
`------------------------------ ADVERSE REACTIONS ------------------------------
`
`
`
` Adult cSSSI Patients: The most common adverse reactions that
`
`
`occurred in ≥2% of adult cSSSI patients receiving CUBICIN
`
`
`
`4 mg/kg were diarrhea, headache, dizziness, rash, abnormal liver
`function tests, elevated creatine phosphokinase (CPK), urinary
`tract infections, hypotension, and dyspnea. (6.1)
`
` Pediatric cSSSI Patients: The most common adverse reactions
`
`
`that occurred in ≥2% of pediatric patients receiving CUBICIN were
`
`
`
`diarrhea, vomiting, abdominal pain, pruritus, pyrexia, elevated
`
`CPK, and headache. (6.1)
`
` Adult S. aureus bacteremia/endocarditis Patients: The most
`
`
`common adverse reactions that occurred in ≥5% of S. aureus
`
`bacteremia/endocarditis patients receiving CUBICIN 6 mg/kg
`
`were sepsis, bacteremia, abdominal pain, chest pain, edema,
`
`pharyngolaryngeal pain, pruritus, increased sweating, insomnia,
`
`
`elevated CPK, and hypertension. (6.1)
`
` Pediatric S. aureus bacteremia Patients: The most common
`
`
`
`
`adverse reactions that occurred in ≥5% of pediatric patients
`
`
`receiving CUBICIN were vomiting and elevated CPK. (6.1)
`
`To report SUSPECTED ADVERSE REACTIONS, contact Merck
`
`Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-
`
`888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
`
`See 17 for PATIENT COUNSELING INFORMATION.
`
`
`Revised: 10/2021
`
`
`
`
`

`

`
` FULL PRESCRIBING INFORMATION: CONTENTS*
`
`1
` INDICATIONS AND USAGE
`1.1 Complicated Skin and Skin Structure Infections (cSSSI)
`
`Bloodstream
`1.2 Staphylococcus
`Infections
`
`
`aureus
`(Bacteremia) in Adult Patients, Including those with Right-
`
`
`Infective Endocarditis, Caused by Methicillin-
`
`Sided
`Susceptible and Methicillin-Resistant Isolates
`
`Infections
`
`Bloodstream
`1.3 Staphylococcus
`
`aureus
`(Bacteremia) in Pediatric Patients (1 to 17 Years of Age)
`
`
`1.4 Limitations of Use
`
`1.5 Usage
`
`2 DOSAGE AND ADMINISTRATION
`
`
`Important Administration Duration Instructions
`
`2.1
`2.2 Dosage in Adults for cSSSI
`
`2.3 Dosage in Pediatric Patients (1 to 17 Years of Age) for
`
`
`cSSSI
`
`
`2.4 Dosage in Adult Patients with Staphylococcus aureus
`
`
`Bloodstream Infections (Bacteremia), Including Those with
`
`Right-Sided Infective Endocarditis, Caused by Methicillin-
`
`Susceptible and Methicillin-Resistant Isolates
`
`2.5 Dosage in Pediatric Patients (1 to 17 Years of Age) with
`
`
`
`Bloodstream
`Infections
`
`
`aureus
`Staphylococcus
`(Bacteremia)
`
`
`2.6 Dosage in Patients with Renal Impairment
`
`
`2.7 Preparation and Administration of CUBICIN
`
`2.8 Compatible Intravenous Solutions
`
`Incompatibilities
`
`2.9
`
`3 DOSAGE FORMS AND STRENGTHS
`4 CONTRAINDICATIONS
`
`5 WARNINGS AND PRECAUTIONS
`
`5.1 Anaphylaxis/Hypersensitivity Reactions
`
`5.2 Myopathy and Rhabdomyolysis
`
`5.3 Eosinophilic Pneumonia
`
`5.4 Drug Reaction with Eosinophilia and Systemic Symptoms
`
`
`
`(DRESS)
`
`
`5.5 Tubulointerstitial Nephritis (TIN)
`
`5.6 Peripheral Neuropathy
`
`5.7 Potential Nervous System and/or Muscular System Effects
`
`
`in Pediatric Patients Younger than 12 Months
`
`
`
`
`
`
`
`
`
`
`5.8 Clostridioides difficile-Associated Diarrhea
`
`
`5.9 Persisting or Relapsing S. aureus Bacteremia/Endocarditis
`
`5.10 Decreased Efficacy in Patients with Moderate Baseline
`
`
`Renal Impairment
`
`5.11 Increased International Normalized Ratio (INR)/Prolonged
`
`Prothrombin Time
`
`5.12 Development of Drug-Resistant Bacteria
`
`6 ADVERSE REACTIONS
`
`6.1 Clinical Trials Experience
`
`6.2 Post-Marketing Experience
`
`7 DRUG INTERACTIONS
`7.1 HMG-CoA Reductase Inhibitors
`
`7.2 Drug-Laboratory Test Interactions
`
`8 USE IN SPECIFIC POPULATIONS
`8.1 Pregnancy
`
`8.2 Lactation
`
`8.4 Pediatric Use
`
`8.5 Geriatric Use
`
`
`8.6 Patients with Renal Impairment
`
`10 OVERDOSAGE
`
`11 DESCRIPTION
`
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`
`12.2 Pharmacodynamics
`
`12.3 Pharmacokinetics
`
`12.4 Microbiology
`
`13 NONCLINICAL TOXICOLOGY
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`
`13.2 Animal Toxicology and/or Pharmacology
`
`14 CLINICAL STUDIES
`14.1 Complicated Skin and Skin Structure Infections
`
`14.2 S. aureus Bacteremia/Endocarditis
`
`15 REFERENCES
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`
`17 PATIENT COUNSELING INFORMATION
`
`
`*Sections or subsections omitted from the full prescribing information
`
`are not listed.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 4878697
`
`

`

`
`
`
`
` FULL PRESCRIBING INFORMATION
`
`1
`
`INDICATIONS AND USAGE
`
`1.1 Complicated Skin and Skin Structure Infections (cSSSI)
`CUBICIN® is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with
`
`
`
`
`complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following
`
`
`
`Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus
`
`pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus
`
`
`
`
`
`faecalis (vancomycin-susceptible isolates only).
`
`
`1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia) in Adult Patients, Including
`
`
`Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and
`
`
`
`
`Methicillin-Resistant Isolates
`CUBICIN is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream
`
`
`
`infections (bacteremia), including adult patients with right-sided infective endocarditis, caused by
`
`methicillin-susceptible and methicillin-resistant isolates.
`1.3 Staphylococcus aureus Bloodstream Infections (Bacteremia) in Pediatric Patients (1 to 17
`
`Years of Age)
`CUBICIN is indicated for the treatment of pediatric patients (1 to 17 years of age) with Staphylococcus
`
`
`
`aureus bloodstream infections (bacteremia).
`
`
`1.4 Limitations of Use
`
`CUBICIN is not indicated for the treatment of pneumonia.
`
`CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The
`
`
`
`clinical trial of CUBICIN in adult patients with S. aureus bloodstream infections included limited data from
`
`
`
`patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Studies
`(14.2)]. CUBICIN has not been studied in patients with prosthetic valve endocarditis.
`CUBICIN is not recommended in pediatric patients younger than 1 year of age due to the risk of
`
`
`
`
`potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or
`
`
`central) observed in neonatal dogs [see Warnings and Precautions (5.7) and Nonclinical Toxicology
`
`
`(13.2)].
`
`1.5 Usage
`
`Appropriate specimens for microbiological examination should be obtained in order to isolate and identify
`
`the causative pathogens and to determine their susceptibility to daptomycin.
`
`
`To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and
`
`
`other antibacterial drugs, CUBICIN should be used only to treat or prevent infections that are proven or
`
`
`
`strongly suspected to be caused by susceptible bacteria.
`
`When culture and susceptibility information is available, it should be considered in selecting or modifying
`
`
`
`
`antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may
`
`contribute to the empiric selection of therapy. Empiric therapy may be initiated while awaiting test results.
`
`
`2
`
`DOSAGE AND ADMINISTRATION
`
`Important Administration Duration Instructions
`2.1
`Adults
`
`Reference ID: 4878697
`
`3
`
`
`

`

`
`
` Administer the appropriate volume of the reconstituted CUBICIN (concentration of 50 mg/mL) to adult
`
`
`
` patients intravenously either by injection over a two (2) minute period or by intravenous infusion over a
`
`
`
`
`
`thirty (30) minute period [see Dosage and Administration (2.2, 2.4, 2.7)].
`Pediatric Patients (1 to 17 Years of Age)
`
`
`
`
`
`
`Unlike in adults, do NOT administer CUBICIN by injection over a two (2) minute period to pediatric
`
`patients.
`
`
` Pediatric Patients 7 to 17 years of Age: Administer CUBICIN intravenously by infusion over a 30-
`
`minute period [see Dosage and Administration (2.3, 2.5, 2.7)].
`
`
`
` Pediatric Patients 1 to 6 years of Age: Administer CUBICIN intravenously by infusion over a 60-
`
`minute period [see Dosage and Administration (2.3, 2.5, 2.7)].
`
`
`2.2 Dosage in Adults for cSSSI
`
`Administer CUBICIN 4 mg/kg to adult patients intravenously in 0.9% sodium chloride injection once every
`
`24 hours for 7 to 14 days.
`2.3 Dosage in Pediatric Patients (1 to 17 Years of Age) for cSSSI
`The recommended dosage regimens based on age for pediatric patients with cSSSI are shown in Table
`
`
`1. Administer CUBICIN intravenously in 0.9% sodium chloride injection once every 24 hours for up to 14
`
`
`
`
`days.
`
`
`Table 1: Recommended Dosage of CUBICIN in Pediatric Patients (1 to 17 Years of Age) with cSSSI,
`Based on Age
`
`
`Dosage Regimen*
`
`Duration of therapy
`
`
`Age Range
`
`12 to 17 years 5 mg/kg once every 24 hours infused over 30 minutes
`
`7 mg/kg once every 24 hours infused over 30 minutes
`7 to 11 years
`
`9 mg/kg once every 24 hours infused over 60 minutes
`2 to 6 years
`10 mg/kg once every 24 hours infused over 60 minutes
`1 to less than 2
`
`
`years
`
`*Recommended dosage regimen is for pediatric patients (1 to 17 years of age) with normal renal function.
`
`Dosage adjustment for pediatric patients with renal impairment has not been established.
`
`Up to 14 days
`
`
`
`
`
`
`
`2.4 Dosage in Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia),
`
`
`Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible
`and Methicillin-Resistant Isolates
`
`Administer CUBICIN 6 mg/kg to adult patients intravenously in 0.9% sodium chloride injection once every
`
`
`
`24 hours for 2 to 6 weeks. There are limited safety data for the use of CUBICIN for more than 28 days of
`
`
`
`
`therapy. In the Phase 3 trial, there were a total of 14 adult patients who were treated with CUBICIN for
`
`more than 28 days.
`
`
`2.5 Dosage in Pediatric Patients (1 to 17 Years of Age) with Staphylococcus aureus
`Bloodstream Infections (Bacteremia)
`
`
`The recommended dosage regimens based on age for pediatric patients with S. aureus bloodstream
`
`
`infections (bacteremia) are shown in Table 2. Administer CUBICIN intravenously in 0.9% sodium chloride
`
`injection once every 24 hours for up to 42 days.
`Table 2: Recommended Dosage of CUBICIN in Pediatric Patients (1 to 17 Years of Age) with S.
`
`
`aureus Bacteremia, Based on Age
`
`Reference ID: 4878697
`
`4
`
`
`

`

`
`
`
`
` Age group
`
`
`
` Dosage*
`
`Duration of therapy
`
`
`12 to 17 years 7 mg/kg once every 24 hours infused over 30 minutes
`
`
`7 to 11 years 9 mg/kg once every 24 hours infused over 30 minutes
`
`12 mg/kg once every 24 hours infused over 60 minutes
`1 to 6 years
`*Recommended dosage is for pediatric patients (1 to 17 years of age) with normal renal function. Dosage
`
`adjustment for pediatric patients with renal impairment has not been established.
`
`Up to 42 days
`
`
`2.6 Dosage in Patients with Renal Impairment
`Adult Patients:
`
`
` No dosage adjustment is required in adult patients with creatinine clearance (CLCR) greater than or equal
` to 30 mL/min. The recommended dosage regimen for CUBICIN in adult patients with CLCR less than
`
`
`
`30 mL/min, including adult patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD),
`
`
`is 4 mg/kg (cSSSI) or 6 mg/kg (S. aureus bloodstream infections) once every 48 hours (Table 3). When
`
`
`
`
`
`
`
`possible, CUBICIN should be administered following the completion of hemodialysis on hemodialysis
`
`
`
`
`days [see Warnings and Precautions (5.2, 5.10), Use in Specific Populations (8.6), and Clinical
`Pharmacology (12.3)].
`
`
`Table 3: Recommended Dosage of CUBICIN in Adult Patients
`Dosage Regimen in Adults
` S. aureus Bloodstream Infections
`
`
`
`cSSSI
`
`Creatinine
`Clearance
`
`(CLCR)
`
`Greater than or
`equal to
`
`30 mL/min
`Less than
`30 mL/min,
`including
`
`hemodialysis
`
`and CAPD
`
`*When possible, administer CUBICIN following the completion of hemodialysis on hemodialysis days.
`
`
`4 mg/kg once
`every 24 hours
`
`
`4 mg/kg once
`
`every 48 hours*
`
`6 mg/kg once every 24 hours
`
`
`6 mg/kg once every 48 hours*
`
`Pediatric Patients:
`
`
`The dosage regimen for CUBICIN in pediatric patients with renal impairment has not been established.
`
`2.7 Preparation and Administration of CUBICIN
`
`
`There are other formulations of daptomycin that have differences concerning reconstitution and
`storage. Carefully follow the reconstitution and storage procedures described in this labeling.
`Reconstitution of CUBICIN Vial
`
`
`
`CUBICIN is supplied in single-dose vials, each containing 500 mg daptomycin as a sterile, lyophilized
`
`
`
`
`
`powder. The contents of a CUBICIN vial should be reconstituted, using aseptic technique, to 50 mg/mL
`
`as follows:
`
`
`
`1. To minimize foaming, AVOID vigorous agitation or shaking of the vial during or after
`reconstitution.
`
`2. Remove the polypropylene flip-off cap from the CUBICIN vial to expose the central portion of the
`
`rubber stopper.
`
`Reference ID: 4878697
`
`5
`
`
`

`

`
`
` 3. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to
`
` dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface.
`
`
`4. Slowly transfer 10 mL of 0.9% sodium chloride injection through the center of the rubber stopper
`
`
` into the CUBICIN vial, pointing the transfer needle toward the wall of the vial. It is recommended
` that a beveled sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless
`
`
`device is used, pointing the transfer needle toward the wall of the vial.
` 5. Ensure that all of the CUBICIN powder is wetted by gently rotating the vial.
`1. Allow the wetted product to stand undisturbed for 10 minutes.
`2. Gently rotate or swirl the vial contents for a few minutes, as needed, to obtain a completely
`
`
`reconstituted solution.
`
`
`
`
`
`
` Administration Instructions
`
`
`Parenteral drug products should be inspected visually for particulate matter prior to administration.
`Slowly remove reconstituted liquid (50 mg daptomycin/mL) from the vial using a beveled sterile needle
`
`that is 21 gauge or smaller in diameter. Administer as an intravenous injection or infusion as described
`
`
`
`
`
`below:
`Adults
`
`Intravenous Injection over a period of 2 minutes
` For intravenous (IV) injection over a period of 2 minutes in adult patients only: Administer the
`
`
`
`appropriate volume of the reconstituted CUBICIN (concentration of 50 mg/mL).
`
`
`Intravenous Infusion over a period of 30 minutes
` For IV infusion over a period of 30 minutes in adult patients: The appropriate volume of the
`
`
`
`
`
`reconstituted CUBICIN (concentration of 50 mg/mL) should be further diluted, using aseptic
`
`
`
`technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride injection.
`
`Pediatric Patients (1 to 17 Years of Age)
`
`Intravenous Infusion over a period of 30 or 60 minutes
` Unlike in Adults, do NOT administer CUBICIN by injection over a two (2) minute period to
`
`
`
`pediatric patients [see Dosage and Administration (2.1)].
` For Intravenous infusion over a period of 60 minutes in pediatric patients 1 to 6 years of age: The
`
`
`appropriate volume of the reconstituted CUBICIN (concentration of 50 mg/mL) should be further
`
`
`
`
`diluted, using aseptic technique, into an intravenous infusion bag containing 25 mL of 0.9% sodium
`
`
`
`
`
`
`chloride injection. The infusion rate should be maintained at 0.42 mL/minute over the 60-minute
`
`period.
` For Intravenous infusion over a period of 30 minutes in pediatric patients 7 to 17 years of age: The
`
`
`appropriate volume of the reconstituted CUBICIN (concentration of 50 mg/mL) should be further
`
`
`
`
`diluted, using aseptic technique, into a 50 mL IV infusion bag containing 0.9% sodium chloride
`
`
`
`injection. The infusion rate should be maintained at 1.67 mL/minute over the 30-minute period.
`
`No preservative or bacteriostatic agent is present in this product. Aseptic technique must be used in the
`
`
`
`preparation of final IV solution. Do not exceed the In-Use storage conditions of the reconstituted and
`
`
`
`diluted solutions of CUBICIN described below. Discard unused portions of CUBICIN.
`
`In-Use Storage Conditions for CUBICIN Once Reconstituted in Acceptable Intravenous Diluents
`Stability studies have shown that the reconstituted solution is stable in the vial for 12 hours at room
`
`
`temperature and up to 48 hours if stored under refrigeration at 2C to 8C (36 to 46F).
`
`
`
`
`Reference ID: 4878697
`
`6
`
`
`

`

`
`
`
`
`
`The diluted solution is stable in the infusion bag for 12 hours at room temperature and 48 hours if stored
`
`
`
`under refrigeration. The combined storage time (reconstituted solution in vial and diluted solution in
`
`infusion bag) should not exceed 12 hours at room temperature or 48 hours under refrigeration.
`
`
`2.8 Compatible Intravenous Solutions
`
`CUBICIN is compatible with 0.9% sodium chloride injection and Lactated Ringer’s injection.
`
`Incompatibilities
`2.9
`CUBICIN is not compatible with dextrose-containing diluents.
`
`
`
`
`
`CUBICIN should not be used in conjunction with ReadyMED® elastomeric infusion pumps. Stability
`
`
`
`
`studies of CUBICIN solutions stored in ReadyMED® elastomeric infusion pumps identified an impurity (2-
`mercaptobenzothiazole) leaching from this pump system into the CUBICIN solution.
`
`
`
`Because only limited data are available on the compatibility of CUBICIN with other IV substances,
`
`
`
`
`additives and other medications should not be added to CUBICIN single-dose vials or infusion bags, or
`
`infused simultaneously with CUBICIN through the same IV line. If the same IV line is used for sequential
`
`
`
`infusion of different drugs, the line should be flushed with a compatible intravenous solution before and
`after infusion with CUBICIN.
`
`3
`DOSAGE FORMS AND STRENGTHS
`
`
`For Injection: 500 mg daptomycin as a sterile, pale yellow to light brown lyophilized powder for
`
`reconstitution in a single-dose vial.
`
`4
`CONTRAINDICATIONS
`CUBICIN is contraindicated in patients with known hypersensitivity to daptomycin [see Warnings and
`
`
`
`Precautions (5.1)].
`
`5 WARNINGS AND PRECAUTIONS
`
`
`5.1 Anaphylaxis/Hypersensitivity Reactions
`
`Anaphylaxis/hypersensitivity reactions have been reported with the use of antibacterial agents, including
`
`CUBICIN, and may be life-threatening. If an allergic reaction to CUBICIN occurs, discontinue the drug
`
`and institute appropriate therapy [see Adverse Reactions (6.2)].
`
`
`5.2 Myopathy and Rhabdomyolysis
`
`Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine
`
`
`phosphokinase (CPK) values to greater than 10 times the upper limit of normal (ULN), has been reported
`
`
`
`with the use of CUBICIN. Rhabdomyolysis, with or without acute renal failure, has been reported [see
`Adverse Reactions (6.2)].
`Patients receiving CUBICIN should be monitored for the development of muscle pain or weakness,
`
`
`
`particularly of the distal extremities. In patients who receive CUBICIN, CPK levels should be monitored
`
`
`
`weekly, and more frequently in patients who received recent prior or concomitant therapy with an HMG-
`
`CoA reductase inhibitor or in whom elevations in CPK occur during treatment with CUBICIN.
`In adult patients with renal impairment, both renal function and CPK should be monitored more frequently
`
`
`than once weekly [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
`
`In Phase 1 studies and Phase 2 clinical trials in adults, CPK elevations appeared to be more frequent
`
`
`
`
`when CUBICIN was dosed more than once daily. Therefore, CUBICIN should not be dosed more
`
`
`
`
`
`
`
`frequently than once a day.
`
`Reference ID: 4878697
`
`7
`
`
`

`

`
`
`
`
`
`
`
`
`CUBICIN should be discontinued in patients with unexplained signs and symptoms of myopathy in
`
`
`conjunction with CPK elevations to levels >1,000 U/L (~5× ULN), and in patients without reported
`
`symptoms who have marked elevations in CPK, with levels >2,000 U/L (≥10× ULN).
`
`In addition, consideration should be given to suspending agents associated with rhabdomyolysis, such as
`
`HMG-CoA reductase inhibitors, temporarily in patients receiving CUBICIN [see Drug Interactions (7.1)].
`
`5.3 Eosinophilic Pneumonia
`
`
`Eosinophilic pneumonia has been reported in patients receiving CUBICIN [see Adverse Reactions (6.2)].
`
`In reported cases associated with CUBICIN, patients developed fever, dyspnea with hypoxic respiratory
`
`
`insufficiency, and diffuse pulmonary infiltrates or organizing pneumonia. In general, patients developed
`
`
`
`
`
`eosinophilic pneumonia 2 to 4 weeks after starting CUBICIN and improved when CUBICIN was
`discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure
`
`has been reported. Patients who develop these signs and symptoms while receiving CUBICIN should
`
`undergo prompt medical evaluation, and CUBICIN should be discontinued immediately. Treatment with
`systemic steroids is recommended.
`
`5.4 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
`DRESS has been reported in post-marketing experience with CUBICIN [see Adverse Reactions (6.2)].
`
`
`
`Patients who develop skin rash, fever, peripheral eosinophilia, and systemic organ (for example, hepatic,
`
`renal, pulmonary) impairment while receiving CUBICIN should undergo medical evaluation. If DRESS is
`suspected, discontinue CUBICIN promptly and institute appropriate treatment.
`
`5.5 Tubulointerstitial Nephritis (TIN)
`
`
`
`TIN has been reported in post-marketing experience with CUBICIN [see Adverse Reactions (6.2)].
`
`
`
`
`Patients who develop new or worsening renal impairment while receiving CUBICIN should undergo
`
`medical evaluation. If TIN is suspected, discontinue CUBICIN promptly and institute appropriate
`
`treatment.
`
`
`5.6 Peripheral Neuropathy
`
`Cases of peripheral neuropathy have been reported during the CUBICIN postmarketing experience [see
`
`
`
`
`
`Adverse Reactions (6.2)]. Therefore, physicians should be alert to signs and symptoms of peripheral
`
`neuropathy in patients receiving CUBICIN. Monitor for neuropathy and consider discontinuation.
`
`
`
`5.7 Potential Nervous System and/or Muscular System Effects in Pediatric Patients Younger
`
`than 12 Months
`
`
`
`
`
`Avoid use of CUBICIN in pediatric patients younger than 12 months due to the risk of potential effects on
`
`
`
`muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal
`
`dogs with intravenous daptomycin [see Nonclinical Toxicology (13.2)].
`
`5.8 Clostridioides difficile-Associated Diarrhea
`
`
`
`
`
`Clostridioides difficile–associated diarrhea (CDAD) has been reported with the use of nearly all systemic
`antibacterial agents, including CUBICIN, and may range in severity from mild diarrhea to fatal colitis [see
`
`
`
`Adverse Reactions (6.2)]. Treatment with antibacterial agents alters the normal flora of the colon, leading
`to overgrowth of C. difficile.
`
`
`C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing
`
`
`
`
`
`
`
`
`
`
`strains of C. difficile cause increased morbidity and mortality, since these infections can be refractory to
`
`
`antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present
`
`
`
`
`with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been
`reported to occur more than 2 months after the administration of antibacterial agents.
`
`Reference ID: 4878697
`
`8
`
`
`

`

`
`
` If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to
`
`
`
`
`
` be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial
`treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
`
` 5.9 Persisting or Relapsing S. aureus Bacteremia/Endocarditis
`
`
`
`
`
` Patients with persisting or relapsing S. aureus bacteremia/endocarditis or poor clinical response should
`
` have repeat blood cultures. If a blood culture is positive for S. aureus, minimum inhibitory concentration
`
` (MIC) susceptibility testing of the isolate should be performed using a standardized procedure, and
`
`
`diagnostic evaluation of the patient should be performed to rule out sequestered foci of infection.
`
`Appropriate surgical intervention (e.g., debridement, removal of prosthetic devices, valve replacement
`surgery) and/or consideration of a change in antibacterial regimen may be required.
`
`
`Failure of treatment due to persisting or relapsing S. aureus bacteremia/endocarditis may be due to
`
`
`reduced daptomycin susceptibility (as evidenced by increasing MIC of the S. aureus isolate) [see Clinical
`
`
`Studies (14.2)].
`
`
`5.10 Decreased Efficacy in Patients with Moderate Baseline Renal Impairment
`
`Limited data are available from the two Phase 3 complicated skin and skin structure infection (cSSSI)
`trials regarding clinical efficacy of CUBICIN treatment in adult patients with creatinine clearance (CLCR)
`
`
`<50 mL/min; only 31/534 (6%) patients treated with CUBICIN in the intent-to-treat (ITT) population had a
`baseline CLCR <50 mL/min. Table 4 shows the number of adult patients by renal function and treatment
`
`
`
`
`
`group who were clinical successes in the Phase 3 cSSSI trials.
`
`
`Table 4: Clinical Success Rates by Renal Function and Treatment Group in Phase 3 cSSSI
`Trials in Adult Patients (Population: ITT)
`Success Rate
`n/N (%)
`
`
`CLCR
`
`
`50-70 mL/min
`30-<50 mL/min
`
`
`
` CUBICIN
`
` 4 mg/kg every 24h
`25/38 (66%)
`7/15 (47%)
`
`
`
` Comparator
`
`30/48 (63%)
`20/35 (57%)
`
` In a subgroup analysis of the ITT population in the Phase 3 S. aureus bacteremia/endocarditis trial,
`
`
`
`
`
`clinical success rates, as determined by a treatment-blinded Adjudication Committee [see Clinical Studies
`
`
`(14.2)], in the CUBICIN-treated adult patients were lower in patients with baseline CLCR <50 mL/min (see
`
`
`Table 5). A decrease of the magnit

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket